Mankind Pharma Q2 & H1 FY27: Revenue Up 17.3% YoY to ₹4,338 Crore; PAT Grows 37.7%
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Crore, up 17.3% YoY. PAT surged 37.7% to ₹716 Crore. H1 FY27 revenue grew 15.1% to ₹8,368 Crore, with PAT up 33.7% to ₹1,290 Crore. Domestic business (ex-CH) grew 15.9% in Q2 FY27, while international business rose 33%. The company made a strategic entry into CAR-T therapies.
Significant revenue and profit growth, coupled with strategic expansion into a new therapy area, are material events that are likely to have a high impact on investor perception and the company's future prospects.
The company reported strong year-on-year growth in revenue and profits for both Q2 and H1 FY27, indicating positive financial performance. The strategic acquisition also adds to the positive outlook.
Mankind Pharma Limited announced its financial results for the second quarter (Q2) and first half (H1) of the fiscal year 2027 (FY27), concluding on September 30, 2026.
For Q2 FY27, the company reported a significant 17.3% year-on-year (YoY) growth in revenue from operations, reaching ₹4,338 Crore, up from ₹3,697 Crore in Q2 FY26. Profit After Tax (PAT) saw a substantial increase of 37.7% YoY to ₹716 Crore, compared to ₹520 Crore in the same period last year. EBITDA also grew by 27.2% YoY to ₹1,175 Crore. The company's domestic business, excluding consumer healthcare, grew by 15.9% YoY, driven by strong performance in its cardiac and diabetes segments. The international business expanded by 33% YoY.
In H1 FY27, revenue from operations grew by 15.1% YoY to ₹8,368 Crore from ₹7,268 Crore in H1 FY26. PAT for H1 FY27 increased by 33.7% YoY to ₹1,290 Crore from ₹965 Crore in H1 FY26. EBITDA for the half-year grew by 26.0% YoY to ₹2,235 Crore.
The investor presentation highlighted key financial metrics, including gross margins improving by 160 bps to 72.5%, EBITDA margins by 230 bps to 26.7%, and PAT margins by 210 bps to 15.4% for H1 FY27 compared to H1 FY26. The company also noted a strategic entry into Next-Generation CAR-T therapies with the acquisition of Armed Cell Therapeutics.
Mankind Pharma maintained its #1 rank in prescription share for nine years, with a market share of 15.2% as of MAT Aug’26. The company's domestic business (ex-CH) showed strong growth, with secondary sales growth of 15.7% versus 14.2% IPM in Q2 FY27. Key focused brands across acute and chronic therapies, as well as BSV's key brands, demonstrated healthy growth. The company expanded its portfolio of brands with sales above ₹50 Crore to 63 and brands over ₹100 Crore to 26.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.